The Furoscix ReadyFlow autoinjector (SCP-111) was developed to deliver a subcutaneous furosemide injection as an investigational alternative to the FDA-approved Furoscix on-body infusion device for treating edema in adult patients with chronic heart failure (CHF) or chronic kidney disease.

In August, MannKind acquired scPharmaceuticals, adding the company’s edema therapeutic offering to its portfolio to expand into cardiorenal medicine. Furosemide currently serves as the standard for treating fluid overload in adult patients with chronic heart CHF and CKD.

Now, the company says its ReadyFlow autoinjector would provide a new option for those patients. It would enable them to manage fluid buildup episodes from the convenience of their own home, rather than in a hospital setting. The autoinjector could reduce administration time from five hours to less than 10 seconds, according to a news release.